Cellectis S.A./€ALCLS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cellectis S.A.
Cellectis S.A. is a biotechnology company specializing in gene-editing for cancer immunotherapy. It focuses on developing allogeneic CAR-T cell products designed to address various hematological and solid tumors using its proprietary TALEN gene editing technology. Founded in 1999, Cellectis is headquartered in Paris, France, and operates facilities in both France and the United States, enhancing its global research and development capabilities. The company's strategic positioning is characterized by its focus on creating off-the-shelf CAR-T therapies, aiming to reduce the complexity and cost associated with personalized CAR-T treatments, thereby broadening accessibility to advanced cancer therapies.
- Ticker
- €ALCLS
- Sector
- Health
- Primary listing
- PAR
- Employees
- 227
- Headquarters
- Paris, France
- Website
- www.cellectis.com
Cellectis S.A. Metrics
BasicAdvanced
€76M
-
-€0.58
2.75
-
Price and volume
Market cap
€76M
Beta
2.75
52-week high
€4.73
52-week low
€0.88
Average daily volume
333K
Financial strength
Current ratio
1.366
Quick ratio
1.336
Long term debt to equity
1.76
Total debt to equity
1.957
Interest coverage (TTM)
-7.18%
Profitability
EBITDA (TTM)
-41.797
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-102.34%
Operating margin (TTM)
-90.87%
Effective tax rate (TTM)
0.53%
Revenue per employee (TTM)
€250,720
Management effectiveness
Return on assets (TTM)
-11.67%
Return on equity (TTM)
-94.54%
Valuation
Price to revenue (TTM)
1.755
Price to book
1.86
Price to tangible book (TTM)
1.91
Price to free cash flow (TTM)
-2.49
Free cash flow yield (TTM)
-40.16%
Free cash flow per share (TTM)
-0.401
Growth
Revenue change (TTM)
0.61%
Earnings per share change (TTM)
9.38%
3-year revenue growth (CAGR)
37.11%
10-year revenue growth (CAGR)
-1.51%
3-year earnings per share growth (CAGR)
-30.75%
10-year earnings per share growth (CAGR)
-6.54%
Cellectis S.A. Financial Performance
Revenues and expenses
Cellectis S.A. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.